Suppliers / Agno Pharma Jiangsu

Agno Pharma Jiangsu

China Updated 9 July 2026

The public registers hold a second record for Agno Pharma Jiangsu. The fuller profile, with 12 active US DMFs and 0 valid CEPs, is at Agno Pharma. Figures on this page cover only this record.

Agno Pharma Jiangsu is an API manufacturer based in China. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 7 June 2024 as VAI.

0
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 7 June 2024 VAI US FDA
  • 7 November 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3009530424

What they file, and where

Molecule Regulators Docs
Carmustine SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Carmustine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Agno Pharma Jiangsu

Is Agno Pharma Jiangsu FDA-registered?
One site operated by Agno Pharma Jiangsu carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Agno Pharma Jiangsu's last inspection go?
The most recent inspection on record closed on 7 June 2024 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 2 inspections are on file.
Where does Agno Pharma Jiangsu manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Agno Pharma Jiangsu make?
1 molecule is on record against Agno Pharma Jiangsu, including Carmustine. Each links through to that molecule's full manufacturer list.
Which regulators recognise Agno Pharma Jiangsu's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Checking Agno Pharma Jiangsu?

Ask Fred what the record holds on Agno Pharma Jiangsu, including filings and inspection history.

Chat with Fred, your AI analyst
Opens WhatsApp. Free to start.

Open risk flags

  • The most recent inspection outcome was VAI, on 7 June 2024.

Comparable suppliers

Astrazeneca Pharmaceutical also in China Changzhou Syntheall Pharmaceutical also in China Changzhou Yinsheng Pharmaceutical also in China Chengdu Shuode Pharmaceutical also in China Chia Tai Tianqing Pharmaceutical Group also in China

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates